Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of 89.92% is 104% above its 5-year average of 44.12%, around the middle of its 5-year range (-228.92%–466.67%).
24.94% above its 12-month average of 71.97%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2017 (2017-12-31): -55.32%.
EBITDA MARGIN
89.92%
EBITDA MARGIN AVG TTM
71.97%
EBITDA MARGIN AVG 3Y
62.87%
EBITDA MARGIN AVG 5Y
44.12%
EBITDA MARGIN AVG 10Y
22.27%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+24.94%
CURRENT VS 3Y AVG
+43.01%
CURRENT VS 5Y AVG
+103.82%
CURRENT VS 10Y AVG
+303.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Dyne Therapeutics, Inc.
Market Cap
$2.88B
EBITDA Margin
89.92%
TTM Avg
71.97%
3Y Avg
62.87%
5Y Avg
44.12%
Market Cap
$2.87B
EBITDA Margin
22.42%
TTM Avg
17.70%
3Y Avg
-0.76%
5Y Avg
-37.34%
Market Cap
$2.69B
EBITDA Margin
11.88%
TTM Avg
11.88%
3Y Avg
7.44%
5Y Avg
-2.29%
Market Cap
$2.69B
EBITDA Margin
17.42%
TTM Avg
19.36%
3Y Avg
20.74%
5Y Avg
18.34%
Market Cap
$3.09B
EBITDA Margin
-359.19%
TTM Avg
-174.35%
3Y Avg
-417.41%
5Y Avg
-1450.57%
Market Cap
$2.64B
EBITDA Margin
-37.02%
TTM Avg
-37.02%
3Y Avg
-37.02%
5Y Avg
-37.02%
Market Cap
$2.64B
EBITDA Margin
-270.04%
TTM Avg
-444.88%
3Y Avg
-365.27%
5Y Avg
-89273.54%
Market Cap
$3.15B
EBITDA Margin
-1.82%
TTM Avg
-32.91%
3Y Avg
-2154.05%
5Y Avg
-2154.05%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. (DYN) | $2.88B | 89.92% | 71.97% | 62.87% | 44.12% |
| TransMedics Group, Inc. (TMDX)vs › | $2.87B | 22.42% | 17.70% | -0.76% | -37.34% |
| AtriCure, Inc. (ATRC)vs › | $2.87B | 3.20% | -0.69% | -3.43% | -1.09% |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 11.88% | 11.88% | 7.44% | -2.29% |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | 17.42% | 19.36% | 20.74% | 18.34% |
| Amylyx Pharmaceuticals, Inc. (AMLX)vs › | $3.09B | -359.19% | -174.35% | -417.41% | -1450.57% |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | -37.02% | -37.02% | -37.02% | -37.02% |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -270.04% | -444.88% | -365.27% | -89273.54% |
| Arcutis Biotherapeutics, Inc. (ARQT)vs › | $3.15B | -1.82% | -32.91% | -2154.05% | -2154.05% |
| Denali Therapeutics Inc. (DNLI)vs › | $3.16B | -54.45% | -179.51% | -231.98% | -287.87% |
Gross Margin
0.0%
EBITDA Margin
89.9%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2017-12-31 | -55.32% |
| 2017-09-30 | 143.96% |
| 2017-06-30 | 135.36% |
| 2017-03-31 | 104.00% |
| 2016-12-31 | 31.86% |
| 2016-09-30 | 26.56% |
| 2016-06-30 | -228.92% |
| 2016-03-31 | 202.38% |
| 2015-12-31 | 94.93% |
| 2015-09-30 | 43.52% |
| 2015-06-30 | 11.10% |
| 2015-03-31 | 9.34% |
| 2014-12-31 | 6.82% |
| 2014-09-30 | 13.98% |
| 2014-06-30 | -16.12% |
| 2014-03-31 | 11.02% |
| 2013-12-31 | 466.67% |
| 2013-09-30 | 29.37% |
| 2013-06-30 | 1.99% |
| 2013-03-31 | -0.63% |
| 2012-09-30 | 141.26% |
| 2012-06-30 | -489.90% |
| 2012-03-31 | -3.95% |
| 2011-12-31 | -605.04% |
| 2011-09-30 | 16.86% |
| 2011-06-30 | -8.28% |
| 2011-03-31 | 16.04% |
| 2010-12-31 | -6.21% |
| 2010-09-30 | 19.48% |
| 2010-06-30 | 114.16% |
| 2010-03-31 | 47.79% |
| 2009-12-31 | -29.48% |
| 2009-09-30 | 24.76% |
| 2009-06-30 | -91.17% |
| 2009-03-31 | 56.00% |
| 2008-12-31 | 25.41% |
| 2008-09-30 | 64.10% |
| 2008-06-30 | -287.23% |
| 2008-03-31 | -7.24% |
| 2007-12-31 | 26.10% |
| 2007-09-30 | 32.50% |
| 2007-06-30 | 36.05% |
